Core Insights - The "2025 China Top 500 Enterprises" list shows a continuous increase in the threshold for entry, marking the 23rd consecutive rise, reaching 47.96 billion yuan, an increase of 579 million yuan from the previous year [1][2] - The total revenue of the top 500 enterprises reached 110.15 trillion yuan, indicating growth compared to the previous year [1] - The total assets of these enterprises amounted to 460.85 trillion yuan, reflecting a year-on-year growth of 7.46% [1] Industry Structure - There is a notable increase in the number of advanced manufacturing and modern service enterprises included in the list, with 39 new or re-entering companies [2] - The automotive and parts manufacturing, as well as logistics and supply chain sectors, saw the most significant growth, with 6 new entrants [2] Innovation and R&D - The top 500 enterprises invested a total of 1.73 trillion yuan in R&D, achieving a new high in R&D intensity at 1.95%, marking an 8-year consecutive increase [2] - The total number of valid patents held by these enterprises reached 2.2437 million, an increase of 214,000 patents, or 10.54% year-on-year [2] Development Coordination - The contribution to total revenue growth from different sectors is as follows: manufacturing (40.48%), services (40.29%), and other industries (19.23%), indicating coordinated development among various types of enterprises [2] Future Directions for Large Enterprises - Large enterprises are expected to play a leading role in innovation-driven development by increasing stable investments in fundamental research and key technologies [3] - They should also focus on cultivating new productive forces by investing in strategic emerging industries such as AI, bio-manufacturing, and green energy [3] - Large enterprises are encouraged to lead industrial transformation by enhancing digital capabilities across the supply chain [3] - Ensuring the safety and stability of supply chains is crucial, with large enterprises acting as a stabilizing force in the current complex external environment [3]

根据榜单，排名前10位的企业依次为：国家电网、中国石油天然气集团、中国石油化工集团、中国建 筑、中国工商银行、中国农业银行、中国建设银行、中国银行、中国铁路工程集团、京东集团。 发布会上，还同步发布了"2025中国跨国公司100大"及跨国指数、"2025中国战略性新兴产业领军企业 100强"和"2025中国大企业创新100强"等多个榜单。 中国企联党委书记、常务副会长兼秘书长朱宏任介绍，从规模上看，"2025中国企业500强"营业收入达 110.15万亿元，较上一年度有所增加。入围门槛实现23连升，达479.60亿元，提升5.79亿元。资产总额 为460.85万亿元，同比增长7.46%。 9月15日，中国企业联合会、中国企业家协会（以下简称"中国企联"）在北京举行新闻发布会，正式发 布"2025中国企业500强"榜单。这是中国企联连续第24次向社会公布"中国企业500强"榜单。 朱宏任认为，作为产业发展的引领者和市场主体中的"关键少数"，未来，以中国企业500强为代表的大 企业需在以下四个方面更好地发挥其作用： 一是在创新驱动发展中发挥"主引擎"作用。大企业应加大对基础研究和关键共性技术的长期稳定投入， 依托 ...

本报记者 杜雨萌 会上，还同时发布了"2025中国跨国公司100大"及跨国指数、"2025中国战略性新兴产业领军企业100强""2025中国大企业创 新100强"等各项榜单。 据中国企联党委书记、常务副会长兼秘书长朱宏任介绍，从规模上看，2025中国企业500强营业收入达110.15万亿元，较上 年500强有所增加。入围门槛实现23连升，达479.60亿元，提升5.79亿元。资产总额为460.85万亿元，增长7.46%。 从产业结构来看，先进制造业和现代服务业企业入围数量不断增加。2025中国企业500强有39家新入围或重新入围企业， 其中汽车及零部件制造、物流及供应链企业增加最多，共有6家新入围企业。 从创新活力看，其研发强度亦创新高。数据显示，2025中国企业500强共投入研发费用1.73万亿元；研发强度创下1.95%的 新高，连续8年提升。创新成果产出质量继续提升，2025中国企业500强持有有效专利总数224.37万件，比上年增加了21.40万 件，增长了10.54%。 此外，2025中国企业500强发展协调性也有所增强。2025中国企业500强中，制造业、服务业和其他行业对营收总额增长的 贡献分别为 ...

Core Insights - The third Guangdong-Hong Kong-Macao Greater Bay Area Development Business Conference was held, focusing on international supply chain collaboration, global trade risk management, cross-border financial cooperation, and industrial integration [1][2] Group 1: Economic Outlook - The economic total of the Guangdong-Hong Kong-Macao Greater Bay Area is projected to exceed 2 trillion USD by 2024 [1] - Guangdong has over 210,000 registered foreign-invested enterprises, attracting significant foreign investment in sectors such as electronic information, green petrochemicals, and specialized equipment [1] Group 2: Strategic Initiatives - Guangdong aims to respond to external uncertainties with high-quality development, optimizing the business environment to provide transparent and stable conditions for global investors [1] - Hong Kong is positioned as an ideal location for mainland enterprises to build global supply chain centers, with a focus on assisting these enterprises in international expansion [2] Group 3: Industry Collaboration - There is a call for collaboration between Hong Kong, Macao, and mainland cities to optimize international supply chains and enhance regional cooperation through digital and intelligent transformation [2] - The establishment of a high-value supply chain service mechanism in Hong Kong aims to provide one-stop consulting services for mainland enterprises [2]

Core Viewpoint - The article discusses the advancements in the biosynthesis of 1,4-butanediol (BDO) through engineered Escherichia coli, highlighting the challenges and breakthroughs in creating a sustainable production method without antibiotics or inducers [2][3][7]. Group 1: BDO Production Challenges - BDO biosynthesis faces three main challenges: lack of natural BDO-producing microorganisms, significant carbon loss during synthesis, and high dependency on antibiotics and inducers, leading to increased costs [3]. Group 2: Engineering Breakthroughs - Researchers at Zhejiang University have developed a high-efficiency BDO synthesis strain by systematically engineering E. coli, resulting in a production of 0.1 g/L of BDO initially, which was later optimized to 0.82 g/L [6]. - The optimal enzyme combination for BDO production was identified, including enzymes from various bacteria, and a mutant enzyme variant was created that increased BDO yield by 11.19 times [6]. - By knocking out the pdhR gene, the researchers enhanced the conversion efficiency of pyruvate to acetyl-CoA, significantly reducing pyruvate accumulation and increasing BDO yield by 44% to 1.83 g/L [6]. Group 3: Antibiotic-Free Fermentation System - A significant advancement was the development of an antibiotic-free fermentation system, where the researchers utilized E. coli's native transcriptional regulatory elements to drive BDO synthesis without external inducers [7]. - The engineered strain B21-pT19 achieved a remarkable BDO production of 34.63 g/L in a 5 L reactor over 72 hours, maintaining stable yields across multiple fermentation batches without the need for antibiotics or inducers, marking the highest reported level of BDO production to date [7].

Core Viewpoint - Shandong Lukang Pharmaceutical Co., Ltd. is enhancing its innovation capabilities and focusing on biomanufacturing to drive growth and transformation in the pharmaceutical industry [1][2][3] Group 1: Company Overview - Established in 1966, Lukang Pharmaceutical is a major biopharmaceutical enterprise in China, recognized as a key antibiotic research and production base [1] - The company is ranked 51st among Chinese pharmaceutical companies by the Ministry of Industry and Information Technology for 2024 [1] Group 2: Innovation and Product Development - The company has invested heavily in technological innovation, optimizing its product structure with multiple innovative drugs entering clinical trials during the 14th Five-Year Plan [1] - It has approved 35 new generic drugs and achieved consistency evaluation for 85 product specifications, enhancing competitiveness in anti-infection, diabetes, and cardiovascular drugs [1] - The company is transitioning from traditional microbial fermentation to synthetic biology applications, aiming to establish a globally influential biomanufacturing innovation hub [2][5] Group 3: Strategic Partnerships and Collaborations - Lukang Pharmaceutical is strengthening partnerships with renowned universities and research institutions to enhance research and development capabilities [4] - The company has signed strategic cooperation agreements with institutions like Shandong University and Wuhan University to accelerate the development of innovative drugs and high-end formulations [4] Group 4: Technological Advancements - The company is building a comprehensive innovation system that integrates basic research, technology transfer, and industrialization, focusing on synthetic biology technology as a new growth point [3] - It has established a biomanufacturing system characterized by a platform for technology transfer and multiple supporting directions, including the world's first green biomanufacturing project for trans-aconitic acid [5]

Group 1: Support for Private Investment - The State Council emphasizes the importance of private investment in stabilizing employment and the economy, proposing practical measures to enhance private investment vitality and development [1] - Focus areas for private investment include new quality productivity, emerging service industries, and new infrastructure, which are characterized by high marketization, rapid technological iteration, and strong ties to people's livelihoods [2][3] - The government aims to create a fair competitive market environment by removing hidden barriers to private investment and strengthening innovation and financing support [1][3] Group 2: New Quality Productivity and Emerging Service Industries - New quality productivity is centered around technological innovation, including future industries like artificial intelligence and quantum technology, which require collaboration between private and public capital to manage risks and enhance efficiency [2] - Emerging service industries such as health care, digital consumption, and cultural creativity are expected to play a significant role in job creation and improving livelihoods, with private capital being agile in responding to diverse consumer needs [2] Group 3: New Infrastructure Investment - New infrastructure investments are characterized by large scales, long return cycles, and technology intensity, where private capital can introduce advanced management practices and flexible financial tools to enhance efficiency and risk diversification [3] - The government has been optimizing the policy environment to facilitate private investment, including relaxing market access and innovating financing models [3] Group 4: Overseas Comprehensive Service System - The meeting highlights the need to improve the overseas comprehensive service system to support Chinese enterprises in international cooperation and competition, addressing the challenges posed by geopolitical shifts and trade protectionism [4][5] - A comprehensive service support system is deemed necessary to meet the real needs of enterprises going abroad, enhancing their international competitiveness and supporting high-quality economic development [5][6] - The proposed system will integrate resources across legal, financial, and logistical services, establishing service platforms and overseas service stations to better support enterprises in their international endeavors [6]

Core Viewpoint - Zhejiang Province is significantly increasing its support for the exhibition industry, with a focus on high-quality development and consumption upgrade through a series of policy measures outlined in the "Several Measures to Accelerate the Promotion of Exhibition Economy and Consumption" [1][3]. Group 1: Policy Initiatives - The Zhejiang Provincial Department of Commerce has released three batches of exhibition directories this year, indicating a larger scale and number compared to previous years [1]. - The "Several Measures" aim to enhance the branding, internationalization, scale, and specialization of exhibitions in Zhejiang [1]. - By 2027, the measures intend to effectively convert attendees and exhibitors into consumer populations, boosting local consumption [3]. Group 2: Economic Impact - The exhibition industry in Zhejiang is reported to have a 1:9 economic driving effect, where one unit of direct income from exhibitions can generate nine units of related industry income, impacting sectors such as accommodation, catering, transportation, and tourism [3]. - In 2023, Zhejiang hosted 783 large-scale exhibition events, a 340% increase year-on-year, recovering to 83% of the pre-pandemic levels of 2019 [1]. Group 3: Industry Characteristics - Each city in Zhejiang has distinctive exhibitions, such as the West Lake International Expo in Hangzhou and the China-Central and Eastern European Countries Expo in Ningbo, showcasing the region's diverse industrial strengths [1]. - The exhibition industry in Zhejiang is characterized by a shortage of composite talents with international perspectives and industry knowledge, primarily consisting of small and medium-sized enterprises [4]. Group 4: Challenges and Competition - There is a notable issue of homogenization in exhibitions within Zhejiang, with many lacking differentiated themes and overlapping products, leading to insufficient precision in customer matching [5]. - The province is working to attract international exhibition groups, but it requires time to enhance its international competitive capabilities [5].

今年以来，在产业各方的协同努力下，我国生物制造技术快速突破并加快向各领域渗透，政策支持体系 日益完善，产业发展前景更加广阔，展现出生物制造作为未来产业的巨大潜力和强劲动力。 华东理工大学生物反应器工程全国重点实验室叶邦策团队构建基于肿瘤微环境响应的自调控智能工程菌 系统，实现了对肿瘤组织的精准靶向定植；全国首个正式投产的天然产物生物制造示范线在上海化学工 业区启动；吉林化纤（000420）年产3.5万吨生物质人造丝项目一期2万吨生产线全面达产…… 生物制造加速向各领域渗透 今年上半年，伴随基因工程、合成生物学等核心技术的快速进步，生物制造越来越广泛地应用到医药、 材料、农业等多个领域，带动传统生产方式的变革与发展。 在生物医药领域，中国科学院刘陈立团队以沙门氏菌为底盘细胞，利用实体肿瘤细胞相对正常细胞的缺 氧环境，开发了新型的抗肿瘤菌株DB1，能精准识别肿瘤并激活免疫系统；中国科学院刘光慧团队用合 成生物学手段对干细胞的长寿基因通路进行重编程，提高了抗氧化和祖细胞抗衰老等能力…… 在生物基材料领域，上海蓝晶微生物科技有限公司创始人张浩千团队自主研发的生物混动技术体系，使 聚羟基脂肪酸酯（PHA）单位产量与碳源 ...

Core Insights - The article highlights the unique path taken by Yikole Biotechnology in the biomanufacturing sector, emphasizing its successful transition from research to large-scale production, which is critical for survival in the industry [1][2]. Group 1: Company Overview - Yikole has launched nearly 20 products in its ten years of operation, achieving significant market share in several of them [1]. - The company recently completed a strategic investment of 450 million yuan from Guotou Juli [1]. Group 2: Technological Innovation - Yikole has developed a platform-based technology system that integrates design, modification, and application, breaking the "R&D to mass production" bottleneck [2]. - The company has built a library of over 60,000 enzyme entities covering 20 types of industrial reactions, enabling rapid adaptation to different product development needs [2]. Group 3: Product Development - Yikole is the only company approved by the National Health Commission to produce high-end sweetener Steviol Glycoside M using enzyme conversion methods, with new sugar-reduced beverages already launched [3]. - The company has also become one of the first licensed producers of human milk oligosaccharides in China, with its 2'-fucosyllactose receiving approval in October 2023 [3]. Group 4: Market Strategy - Yikole's management team consists of experienced professionals from the biomanufacturing sector, ensuring a unified vision for addressing industry pain points and creating marketable products [4]. - The company is focusing on upstream raw materials like methanol and carbon dioxide, which are not constrained by arable land or food supply, aiming to reduce production costs and promote a green transition [5]. - Yikole is forming joint ventures with leading companies in specific fields to leverage their market resources and facilitate product commercialization [5].